Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920257 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase 1 study of Cancer, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
- 7
- Study locations
NCT00920257 is a Phase 1 study of Cancer that has completed, run by GlaxoSmithKline. The registered enrollment target is 77 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT00920257, a Phase 1 study of Cancer, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is a first time in human, Phase I, open-label, dose-escalation study of the oral AKT inhibitor GSK2141795 in subjects with solid tumors or lymphomas.
Conditions Studied
Interventions
- DRUG GSK2141795
Study Locations (7)
Maryland
- GSK Investigational Site - Baltimore
Massachusetts
- GSK Investigational Site - Boston
New York
- GSK Investigational Site - New York
Oklahoma
- GSK Investigational Site - Oklahoma City
Tennessee
- GSK Investigational Site - Nashville
Texas
- GSK Investigational Site - Houston
Ontario
- GSK Investigational Site - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2009-06-16 |
| Est. Completion | 2013-04-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00920257
The ClinicalTrials.gov registry entry for NCT00920257 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which GSK2141795 is the first listed.
NCT00920257 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Maryland, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT00920257 about?
NCT00920257 is a clinical study titled "A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795". This study is a first time in human, Phase I, open-label, dose-escalation study of the oral AKT inhibitor GSK2141795 in subjects with solid tumors or lymphomas.
What is the current status of trial NCT00920257?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2009-06-16. Estimated completion is 2013-04-17.
What conditions does trial NCT00920257 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT00920257?
The interventions under investigation include: GSK2141795 (DRUG).
Who is sponsoring clinical trial NCT00920257?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00920257 being conducted?
This trial has 7 study locations across Maryland, Massachusetts, New York, Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.